Neurological research · 2025
Characteristics of SAA, the SII and NT-proBNP levels in patients with ACI and their value in evaluating the prognosis of thrombolytic therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Xianshi, Pang Ailan, Liu Wei, Xu Hong
Аннотация
OBJECTIVE: To explore the features of serum amyloid A (SAA), the systemic immune inflammation index (SII), and N-terminal B-type natriuretic peptide (NT-proBNP) among individuals suffering from acute cerebral infarction (ACI), as well as their potential significance in assessing the adverse outcomes of thrombolytic treatment.
METHODS: A total of 122 patients with ACI who underwent thrombolytic therapy were included in this single-center retrospective study. Patients were categorized into short-term good prognosis (n = 81) and short-term adverse outcomes (n = 41) groups on the basis of their prognosis within 6 months after the procedure. Risk factors for poor short-term prognosis after thrombolytic therapy in ACI patients were screened via regression analysis, and the predictive value of each risk factor was assessed via receiver operating characteristic (ROC) curves.
RESULTS: Preoperative SAA, NT-proBNP, Hcy, CRP, and the SII were significantly higher in the short-term adverse outcomes group than in the good prognosis group (p < 0.05). Specifically, the adverse outcomes group had higher mean levels of SAA, NT-proBNP, and SII (p < 0.001). The combined model (SAA, NT-proBNP, and the SII) had high predictive accuracy, with an AUC of 0.957 (p < 0.05).
CONCLUSION: Pretreatment SAA, SII, and NT-proBNP levels are strongly correlated with adverse short-term outcomes of ACI patients following thrombolytic therapy.
METHODS: A total of 122 patients with ACI who underwent thrombolytic therapy were included in this single-center retrospective study. Patients were categorized into short-term good prognosis (n = 81) and short-term adverse outcomes (n = 41) groups on the basis of their prognosis within 6 months after the procedure. Risk factors for poor short-term prognosis after thrombolytic therapy in ACI patients were screened via regression analysis, and the predictive value of each risk factor was assessed via receiver operating characteristic (ROC) curves.
RESULTS: Preoperative SAA, NT-proBNP, Hcy, CRP, and the SII were significantly higher in the short-term adverse outcomes group than in the good prognosis group (p < 0.05). Specifically, the adverse outcomes group had higher mean levels of SAA, NT-proBNP, and SII (p < 0.001). The combined model (SAA, NT-proBNP, and the SII) had high predictive accuracy, with an AUC of 0.957 (p < 0.05).
CONCLUSION: Pretreatment SAA, SII, and NT-proBNP levels are strongly correlated with adverse short-term outcomes of ACI patients following thrombolytic therapy.